CoChat

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.

Shitara, Kohei, Muro, Kei, Watanabe, Jun, Yamazaki, Kentaro, Ohori, Hisatsugu, Shiozawa, Manabu, Yasui, Hirofumi, Oki, Eiji, Sato, Takeo, Naito, Takeshi, Komatsu, Yoshito, Kato, Takeshi, Soeda, Junpei, Yamamoto, Kouji, Yamashita, Riu, Akagi, Kiwamu, Ochiai, Atsushi, Uetake, Hiroyuki, Tsuchihara, Katsuya, Yoshino, Takayuki · 2023 · Journal of Clinical Oncology
Cited by 35

The DOI matches its Crossref record.

Abstract

11 Background: The PARADIGM trial showed longer median overall survival (OS) with first-line mFOLFOX6 plus panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with RAS wild type (WT) and left-sided metastatic colorectal cancer (mCRC) (37.9 vs 34.3 months, respectively; hazard ratio [HR], 0.82; P=0.031) and similar OS in right-sided pts (HR 1.09; Yoshino T, et al. ASCO 2022 LBA1). We evaluated the usefulness of negative hyperselection by gene alterations in ctDNA related to primary resistance to anti-EGFR therapy. Methods: Baseline plasma ctDNA (>10 ng/mL and >10 nM DNA) from pts enrolled in the biomarker study (NCT02394834) was assessed using a custom panel (PlasmaSELECT-R 91, PGDx). Preplanned gene alterations for hyperselection included KRAS, NRAS, PTEN, and extracellular domain EGFR mutations, HER2 and MET amplifications, and ALK, RET, or NTRK1 fusions. Results: Among 802 pts in the full analysis set, 733 (91%) had evaluable pretreatment samples for ctDNA analysis. Of these pts, 204 (28%) had at least 1 gene alteration, including KRAS/NRAS (8%), BRAF V600E (11%), PTEN (5%), EGFR (3%), HER2 (5%), MET (1%), and fusions (1%). In 529 (72%) hyperselected pts without any gene alterations, OS tended to be longer with PAN vs BEV regardless of primary sidedness; the OS HRs ranged from 0.76 to 0.82, and the median OS gains ranged from 6.6 to 8.0 months (Table). Meanwhile, OS was similar or inferior with PAN vs BEV irrespective of the primary sidedness in pts with any of these gene alterations (Table). Conclusions: Negative hyperselection using ctDNA rather than tumor sidedness may identify appropriate pts for first-line PAN over BEV. These results warrant further validation in additional cohorts. Clinical trial information: NCT02394834 . [Table: see text]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2023.41.4_suppl.11

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 35

Metadata

Authors
Shitara, K., Muro, K., Watanabe, J., Yamazaki, K., Ohori, H., Shiozawa, M., Yasui, H., Oki, E., Sato, T., Naito, T., Komatsu, Y., Kato, T., Soeda, J., Yamamoto, K., Yamashita, R., Akagi, K., Ochiai, A., Uetake, H., Tsuchihara, K., & Yoshino, T.
Venue
Journal of Clinical Oncology
Published
2023-02-01
Volume
41
Issue
4_suppl
Pages
11-11
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4317863051
Cited by
35
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. https://app.cochat.ai/papers/10.1200/jco.2023.41.4_suppl.11
The paper
Shitara, K., Muro, K., Watanabe, J., Yamazaki, K., Ohori, H., Shiozawa, M., Yasui, H., Oki, E., Sato, T., Naito, T., Komatsu, Y., Kato, T., Soeda, J., Yamamoto, K., Yamashita, R., Akagi, K., Ochiai, A., Uetake, H., Tsuchihara, K., & Yoshino, T. (2023). Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2023.41.4_suppl.11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.